- 期刊
PSMA正子掃描對於攝護腺癌診療之應用
The Use of PSMA PET in Guiding Further Investigating and Treatment of Prostate Cancer
摘要
攝護腺癌是全球男性癌症發生率第2名的癌症但存活率相對較高的癌症，並需要較精確的影像造影以協助治療決策。目前美國Food and Drug Administration已許可Ga-68 prostate-specific membrane antigen（PSMA）-11與F-18 DCFPyL兩種PSMA正子掃描的追蹤劑。PSMA正子掃描可以用在初次分期的攝護腺癌，其靈敏度與特異度皆高於傳統影像。在生化復發的病人中，可偵測病灶而影響改變53%的放射治療計劃，此外PSMA正子掃描亦可協助治療效果與預後評估。目前攝護腺癌領域的研究不斷發展，配合多參數磁振造影以及Lu-177 PSMA的治療，可以拓展PSMA正子掃描在治療領域的應用。
並列摘要
Prostate cancer is the second most common cancer in men worldwide. Prostate cancer is a cancer with a relatively high survival rate, but because most of the patients have no symptom, medical imaging is needed in treatment decision-making. Currently, the US Food and Drug Administration has approved two prostate-specific membrane antigen (PSMA) positron emission tomography (PET) tracers, Ga-68 PSMA-11 and F-18 DCFPyL. PSMA PET can be used in staging of prostate cancer with higher sensitivity and specificity than conventional medical imaging such as computed tomography and bone scan. In patients with biochemical recurrence, lesions can be detected on PSMA PET and 53% of radiotherapy plans can be changed. In addition, PSMA PET can also be used in the evaluation of treatment effects and prognosis. At present, as the field of prostate cancer continues to develop, combining multiparameter magnetic resonance imaging and Lu-177 PSMA-617 can expand the role of PSMA PET in treatment plan.